Showing 8,841 - 8,860 results of 85,183 for search '(( 50 ((((we decrease) OR (a decrease))) OR (nn decrease)) ) OR ( 2 c decrease ))', query time: 1.63s Refine Results
  1. 8841
  2. 8842
  3. 8843
  4. 8844
  5. 8845
  6. 8846
  7. 8847
  8. 8848
  9. 8849

    Effects of ZL184-treatment on locomotor activity (A-C) and thigmotactic behavior (D-F). by Larisa V. Lysenko (669533)

    Published 2014
    “…<p>In the vehicle-treated animals, locomotor activity was significantly increased in Ts65Dn vs. 2N mice. This can be seen from the increased ambulatory distance (A) and ambulatory time (B) and decreased resting time (C) of Ts Veh vs. 2N Veh group. …”
  10. 8850

    Cell count data for Fig 2. by Zoey K. Wallis (17725175)

    Published 2025
    “…To test this, we administered intracisternal (i.c.) injections of two different colored fluorescent superparamagnetic iron oxide nanoparticles (SPION) to SIV-infected macaques either early in infection (12–14 dpi) or 30 days before necropsy. …”
  11. 8851
  12. 8852
  13. 8853
  14. 8854
  15. 8855
  16. 8856
  17. 8857
  18. 8858
  19. 8859

    Penam Sulfones and β-Lactamase Inhibition: SA2-13 and the Importance of the C2 Side Chain Length and Composition by Elizabeth A. Rodkey (510008)

    Published 2014
    “…We next demonstrated using protein crystallography that increasing the linker length by one carbon allowed for better capture of a <i>trans</i>-enamine intermediate; in contrast, this <i>trans</i>-enamine intermediate did not occur when the C2 linker length was decreased by one carbon. If the linker was altered by both shortening it and changing the carboxyl moiety into a neutral amide moiety, the stable <i>trans</i>-enamine intermediate in <i>wt</i> SHV-1 did not form; this intermediate could only be observed when a deacylation deficient E166A variant was studied. …”
  20. 8860

    Image1_Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates.TIF by Myung-Eui Seo (6822518)

    Published 2023
    “…However, incorporating novel pharmacogenetic variants into guidelines takes considerable time.</p><p>Methods: We comprehensively assessed the drug metabolizing capabilities of CYP2C19 variants discovered through population sequencing of two substrates, S-mephenytoin and omeprazole.…”